SMARCB1 purified MaxPab Mouse Polyclonal Antibody (B01P)
- Known as:
- SMARCB1 enriched MaxPab Mouse Polyclonal Antibody (B01P)
- Catalog number:
- ENZ-006598-B01P
- Product Quantity:
- 0.05mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- SMARCB1 purified MaxPab Mouse Polyclonal Antibody (B01P)
Related genes to: SMARCB1 purified MaxPab Mouse Polyclonal Antibody (B01P)
- Gene:
- SMARCB1 NIH gene
- Name:
- SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
- Previous symbol:
- SNF5L1
- Synonyms:
- BAF47, Ini1, Snr1, hSNFS, Sfh1p, RDT, PPP1R144, SNF5
- Chromosome:
- 22q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-21
- Date modifiied:
- 2019-04-23
Related products to: SMARCB1 purified MaxPab Mouse Polyclonal Antibody (B01P)
Related articles to: SMARCB1 purified MaxPab Mouse Polyclonal Antibody (B01P)
- Variants in SMARCB1, encoding a core subunit of the BAF chromatin remodeling complex, are associated with intellectual developmental disorders, particularly Coffin-Siris Syndrome (CSS), though the genotype-phenotype spectrum remains incompletely defined. This study aims to assess correlations between SMARCB1 variant location and phenotypic manifestations. - Source: PubMed
Publication date: 2026/05/27
Saad RamyGigli Clementina Cobollivan der Sluijs Pleuntje JWilson Jon RHsieh Tzung-ChienMcConnell Vivienne P MBacino CarlosBird Lynne MAdam ShelinClarke LorneCobben Jan MTravessa AndréFaivre LaurenceFarholt StenseGregersen Pernillevan Hasselt JosLahiri NayanaPalmer Elizabeth ESheffer RuthClayton-Smith JillWilnai YaelDeshpande CharuMorton Jenny E VClement EmmaSanten Gijs W EDias Cristina - Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and aggressive pediatric embryonal tumor of the central nervous system with marked histological and immunophenotypic heterogeneity, which can make diagnosis difficult in some cases. This study aimed to summarize the clinicopathological and molecular features of pediatric AT/RT and to evaluate an HE-IHC dual-path deep learning model as an auxiliary diagnostic approach. Clinical, histopathological, immunophenotypic, ultrastructural, and fluorescence in situ hybridization (FISH) data were retrospectively collected from 18 children with AT/RT treated at Beijing Children's Hospital between February 2010 and April 2021. A total of 361 pathological images were used to train and test a ResNet50-based dual-path classification model with transfer learning and feature fusion. An additional independent test set of 175 histological and immunohistochemical images from six newly collected patients was used for supplementary validation. The mean age at diagnosis was 2 years and 3 months. All cases showed loss of INI1 expression, positivity for CK and EMA, and a high Ki-67 index. FISH analysis identified SMARCB1 deletion in 7 of 15 tested cases. In the original image-based test set, the dual-path model achieved an accuracy of 90.91%, compared with 81.82% for the model without transfer learning, 86.36% for the single-path immunohistochemistry model, and 50.00% for the single-path histological model. In the additional independent test set, the trained model correctly classified all 175 images. Pediatric AT/RT shows diverse clinicopathological features and complex SMARCB1 alteration patterns. The HE-IHC dual-path model showed encouraging preliminary performance for auxiliary pathological assessment; however, larger multicenter cohorts with molecular subgroup annotation are needed for further validation before routine clinical application. - Source: PubMed
Publication date: 2026/05/16
Tian JianZhang NanDeng ZhijuanWang JianwenZheng Wentao - Oesophageal adenocarcinoma (OAC) incidence continues to rise in developed countries. Despite advances in deciphering cancer genomes and oncogenic pathways, precision therapies for OAC remain limited. An expansion of precision therapy repertoire in OAC is urgently required. - Source: PubMed
Publication date: 2026/05/25
Sharma SowmyaWong Ho YiJohnston Rebecca LKoufariotis Lambros TWood ScottHollway GeorginaAoude Lauren GDavidson Aimee LPearson John VLin Frank PBarbour Andrew PWaddell Nicola - Poorly differentiated chordoma (PDC) is an exceptionally rare bone tumor with aggressive behavior and early recurrence. Evidence on the role and integration of chemotherapy remains limited. We aimed to share our institutional management experience and identify clinical prognostic factors in PDC. - Source: PubMed
Publication date: 2026/05/21
Xing JingyuZhang HaoYuan ZijieCao XinghaoTan TaoHu JinboZhi WenlanZhao ChenglongYang Cheng - Deficiency of SWI/SNF proteins, particularly BRG1 (SMARCA4) and INI1 (SMARCB1), has frequently been associated with poor clinical outcomes in dedifferentiated/undifferentiated endometrial carcinoma (DDEC/UDEC). However, the prognostic significance of BRM (SMARCA2) remains unclear. Additionally, although the TCGA classification predicts outcomes in endometrioid adenocarcinoma, its prognostic value in DDEC/UDEC is still unproven. In this study, 71 DDEC/UDEC cases were assessed for the expression of BRG1, BRM, INI1 and ARID1A. BRG1, BRM, INI1 and ARID1A deficiency were observed in 36% (26/71), 55% (27/49), 8% (6/69), 55% (19/34) of cases, respectively. BRG1-deficiency, and BRG1 or INI1-deficiency were both associated with poorer overall survival (OS) (P = 0.048, P = 0.013, respectively). Only BRG1 or INI1-deficiency was significantly correlated with worse disease-free survival (DFS) (P = 0.039). No significant differences in either DFS or OS were observed between patients with isolated loss of BRM or INI1 expression and those with intact expression. Genetic alterations in 31 cases predominantly involved the PI3K-AKT-MTOR pathway. TCGA molecular subtyping showed no significant differences in OS (P = 0.488) or DFS (P = 0.425) among the molecular subtypes. However, patients with concurrent microsatellite instability-high (MSI-H) and PIK3CA mutation exhibited more favorable OS (P = 0.021) and DFS (P = 0.012). Therefore, our research shows that BRG1 or INI1 deficiency, especially BRG1 deficiency, predicts a poorer prognosis in patients with DDEC/UDEC. Furthermore, other integrated molecular classification strategies--such as the combination of MSI-H status and PIK3CA mutation--may provide a novel prognostic stratification approach for this aggressive tumor entity. - Source: PubMed
Publication date: 2026/05/19
Qi YuYao QianlanXu YuyinYu LinTu XiaoyuCheng YufanGe HuijuanTang ShaoxianZhou XiaoyanYang WentaoBi Rui